Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Inv. presentation
Auditor change
Credit agrmnt [a]
SPECTRUM PHARMACEUTICALS INC (SPPI) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/09/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update"
11/10/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Update Poziotinib NDA is on track for submission in 2021 under a Fast Track designation"
08/12/2021 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Update Submission of poziotinib NDA on track for later in 2021 under a Fast Track designation"
05/13/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "FDA deferred action on the BLA for ROLONTIS® due to inability to conduct inspection of the manufacturing facility citing COVID-19 related travel restrictions Pre-NDA meeting with FDA is scheduled for poziotinib in NSCLC HER2 exon-20 insertion mutations in previously treated patients"
08/10/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports First Quarter 2020 Financial Results and Pipeline Update BLA for ROLONTIS ® under active FDA review - PDUFA date on October 24, 2020"
11/07/2019 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Pipeline Update Topline data from Cohort 1 of ZENITH20 trial evaluating poziotinib for NSCLC expected in December Basket trial initiated to study poziotinib in patients with EGFR or HER2 mutation-positive malignant solid tumors in an investigator-led study at The University of Texas MD Anderson Cancer Center ROLONTIS ® Biologics License Application submitted on October 24, 2019 HENDERSON, Nevada - - Spectrum Pharmaceuticals, Inc. , a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended September 30, 2019. “Spectrum has an expanding pipeline, significant near-term milestones, solid capitalization and a highly focused team,” said ..."
08/08/2019 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Pipeline Update HENDERSON, Nevada - August 8, 2019 - Spectrum Pharmaceuticals, Inc. , a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2019. “We’ve made significant progress on our pipeline in the last few months,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “Most notably, we completed enrollment in our first two poziotinib cohorts in the ZENITH20 study and expect to see results from cohort 1 in the fourth quarter. Based on strong science, we’ve expanded the poziotinib development program to include additional areas of high unmet medical need in lung cancer. We also had a productive meeting w..."
05/09/2019 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results and Pipeline Update"
08/09/2018 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pipeline Update"
05/03/2018 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update"
11/02/2017 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update"
08/03/2017 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update"
05/02/2017 8-K Form 8-K - Current report
08/09/2016 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Pipeline Update"
05/05/2016 8-K Form 8-K - Current report
11/04/2015 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports Third Quarter 2015 Financial Results and Pipeline Update"
08/06/2015 8-K Quarterly results
Docs: "Spectrum Pharmaceuticals Reports Second Quarter 2015 Financial Results and Pipeline Update"
05/10/2010 8-K Form 8-K - Current report
04/05/2010 8-K Form 8-K - Current report
11/12/2009 8-K Form 8-K - Current report
08/13/2009 8-K Form 8-K - Current report
05/18/2009 8-K Form 8-K - Current report
03/31/2009 8-K Form 8-K - Current report
11/07/2008 8-K Form 8-K - Current report
08/12/2008 8-K Form 8-K - Current report
05/13/2008 8-K Form 8-K - Current report
11/09/2007 8-K Form 8-K - Current report
08/09/2007 8-K Form 8-K - Current report
05/02/2007 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy